FUTURE OF HEALTHCARE

Diversified Medical Healthcare Acquires Mobile App for Employers to Easily Comply with Reinstated OSHA Mandate

DMH | December 23, 2021

With the OSHA mandate for large businesses fast approaching, Diversified Medical Healthcare (DMH) announces their acquisition of a mobile app providing easy solutions for employer mandate compliance. The app, ConfirmD, created by Buddycheque LLC, serves as a digital health wallet for each employee, keeping their medical records in one user-friendly and secure platform. With an administrator dashboard, employers can view the status of COVID-19 testing and vaccinations across their organization at-a-glance, making reporting and compliance streamlined and simple. The app can be implemented in days and will make a drastic difference for businesses and their operations in the weeks and months ahead.

"Throughout the pandemic, we've worked with large businesses and organizations across the nation to effectively handle their COVID-19 management needs. We've kept up with CDC guidelines and FDA regulations to ensure the companies we work with are informed and up to date to implement best practices and keep their employees safe. ConfirmD is just one more way we're helping businesses to stay open and compliant without disruption."

Kevin Murdock, CEO and Founder of Diversified Medical Healthcare

ConfirmD generates custom QR codes for each app user to store their vaccination records and test results in one place. This can be accessed by a facial recognition feature for maximized privacy from any mobile device. The HIPAA compliant platform also has the capability to integrate with any laboratory information management system (LIMS) to enable employees and employers to access COVID-19 results in real-time, as soon as the lab processes the results.

"We acquired ConfirmD because of the diligence that went into the development of this app," added Kevin Murdock. "Buddycheque, LLC integrated leading technology and their years of medical expertise to make this a powerful platform and a turnkey solution for both individuals and employers. We are proud to now offer ConfirmD under Diversified Medical Healthcare."

Buddycheque, LLC, the company which created the ConfirmD app, was founded by Dr. Ramsey Kilani, Karl Wagner, Bob Ramsey, and Alex Chatel – who have amassed years of expertise in the industries of healthcare and tech security. The ConfirmD app is now powered by OnGen medical data management software company, which is a part of the portfolio of Diversified Medical Healthcare companies which deliver innovative solutions for the healthcare industry for molecular diagnostics, medical supplies, laboratory equipment, and medical software.

Buddycheque, LLC co-founder, Ramsey Kilani stated, "We developed this app to make it as simple as possible for people to keep track of their own medical information with cutting edge technology. We are thrilled that this app is now being taken to new heights by Diversified Medical Healthcare, initially in its efforts around the COVID-19 pandemic and for its broader application for the future of healthcare."

During the President's address to the nation yesterday on the Omicron variant, he stated, "We all want this to end, but we're still in it. This is the critical moment. We also have more tools than we've ever had before. We're ready. We'll get through this." ConfirmD is one of these tools now available with the latest technology to help businesses navigate this challenging time. Using ConfirmD could be the difference between the new mandate causing operational disruptions and an accumulation of unwanted fines or a seamless experience in implementing the required compliance regulations.

About Diversified Medical Healthcare 

Diversified Medical Healthcare (DMH), headquartered in Greenville, SC is a holding entity with several portfolio companies providing healthcare solutions for improved patient care nationwide. Offering advanced clinical laboratory services that span throughout the US, their fully accredited laboratories include Premier Medical Laboratory Services, Dynasty Medical Laboratory Services, and First Medical Laboratory Services. DMH also provides medical supply and equipment distribution under Vessel Medical, delivers custom procedure trays for various surgical needs with CPT Medical, and helps to quickly and accurately manage medical data with their medical data software company, OnGen. DMH is your trusted partner providing advanced solutions for a healthier tomorrow. 

Spotlight

Hospital coding departments have seen a dramatic increase in professional fee coding following the wave of physician group acquisitions in recent years. These facility coding teams are highly skilled at inpatient and outpatient coding but are often challenged by the highly specialized physician-orientated coding subset. This issue is gaining increasing scrutiny as sub-optimal professional fee coding is a compliance risk and can negatively impact the bottom lines of the hospital, and the physicians’ practices for which they support.


Other News
HEALTH TECHNOLOGY

Alkem Laboratories Ltd. to Launch State of the Art Technology for Diabetic Foot Ulcer Management

Alkem Laboratories Ltd. | January 13, 2022

Alkem Laboratories Ltd. (Alkem) hereby announces to launch a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on disruptive 4D Bioprinting technology, which would be used to treat deep, non-healing chronic wounds and is expected to be launched in the Indian market in the latter half of 2022 post regulatory approval. This advanced technology for DFU management has a high scope of preventing amputations in diabetic patients. This technology will be available at affordable rates to Indian patients at a time when there is no definitive treatment for DFU in India. India currently has approximately 77 mn diabetes patients, the second highest in the world. A diabetic foot ulcer is one of the most significant and devastating complications of diabetes and is defined as a foot affected by ulceration that is associated with neuropathy and/or peripheral arterial disease of the lower limb in a patient with diabetes. Approximately, 12-15% with diabetes suffer from DFU at least once in a lifetime. 5–24% of them will finally lead to limb amputation within 6–18 months after the first evaluation. The risk of foot ulceration and limb amputation increases with age and the duration of diabetes. Alkem has collaborated with Rokit Healthcare Inc. to commercialize the technology in India to help reduce amputation amongst DFU patients considering the negative impact of amputation on a patient's quality of life and the associated economic burden on the healthcare system. "In India, Diabetes is one of the major healthcare challenges. The challenge in itself is so huge that diabetic foot ulcers often get ignored. Approximately 1 lac people have to undergo amputation every year and compromise on their quality of life. To address the problem, Alkem has collaborated with Rokit Healthcare Inc., a global regenerative solutions company, to bring out novel solutions for the management of diabetic foot ulcers." Mr. Sandeep Singh, Managing Director, Alkem Laboratories Ltd Adding further, Mr. Sandeep asserted, "Alkem, over the years, has always been at the forefront in delivering high-quality patient care, through its innovation and patient-centric initiatives." About Alkem Laboratories Ltd Established in 1973 and headquartered in Mumbai, Alkemis a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The Company also has presence in more than 40 international markets, with the United States being its key focus market.

Read More

MEDICAL DEVICES

CeloNova Announces New Strategic Direction Focused on Creating Partnership

CeloNova BioSciences, Inc. | April 08, 2022

CeloNova BioSciences, Inc. developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene™-F nanocoating, announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking to optimize implant interaction within the body. The company's nanocoated innovation is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date. "We are pleased to offer leading medical device manufacturers access to the unique clinical advantages of our Polyzene-F nanocoated technology that has clinically demonstrated low thrombosis, restenosis and inflammation with rapid healing effects," stated Carl St. Bernard, President and Chief Executive Officer of CeloNova. "This technology offers a significant benefit to companies seeking to improve the clinical performance of their implant technologies." "I fully support CeloNova's new strategic direction which allows medical device manufacturers to benefit from long-term biocompatibility and thromboresistance of Polyzene-F. When my students and I set out to study the hemocompatibility of this inorganic polymer in our lab in Heidelberg Germany, we soon realized its potential to significantly limit a wide range of implant complications and being broadly applied in the human body and in biomedical devices." Professor Dr. Michael Grunze, Former Chair and Professor (emeritus) at the Institute of Applied Physical Chemistry of the Ruprecht-Karls-University in Heidelberg and co-inventor of Polyzene-F CeloNova is based on a rich history of medical innovation with two PzF coated medical implants successfully commercialized in the U.S. and the EU. The company's PzF coated embolic microspheres product line was sold to Boston Scientific in 2015 and the COBRA PzF NanoCoated Coronary Stent, was developed to safely and effectively treat patients who may benefit from 1-month of dual antiplatelet therapy. CeloNova's new business direction builds upon the successful application of PzF in interventional oncology and cardiology and expands its opportunities through the development of new surface coating technologies to address important unmet clinical needs. "In my pre-clinical research at CVPath since 2012, CeloNova's proprietary Polyzene-F coating has consistently demonstrated a unique advantage of allowing an implant to heal quickly and in a functional way, without the need for antiproliferative drug elution," stated Aloke Finn, MD, Medical Director and Chief Scientific Officer at CVPath and Associate Professor of Medicine at the University of Maryland. "I believe Polyzene-F will continue to play an important role in delivering safety and efficacy in clinical practice." Polyzene-F is a proprietary, ultra-pure and highly elastic surface coating possessing unique mechanical properties that allow an implant to be coated at a nanoscale level. The coating acts as a biocompatible barrier between the implant, intimal surface and circulating elements in the blood and has demonstrated thromboresistant and anti-inflammatory properties with significantly faster, higher quality healing compared to market-leading technologies.1* About CeloNova BioSciences, Inc. CeloNova BioSciences, Inc. is a global medical device company that develops, manufactures and markets novel surfaced coated technologies, including its proprietary Polyzene™-F nanocoating. The next generation nanocoating is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date.

Read More

MEDICAL DEVICES

Lark Health Builds AI-Driven Heart Health Program

Lark Health | March 17, 2022

Lark Health today announced the development of a novel AI-driven program for the prevention and management of atherosclerotic cardiovascular disease and coronary artery disease in collaboration with Roche Diagnostics. The program, named Lark Heart Health, is an AI-driven virtual care solution that provides personalized health coaching anytime, anywhere. The new Heart Health program is planned to launch later this year. Cardiovascular disease is the leading cause of death globally, and nearly half of all adults in the U.S. have some form of CVD. It's also one of the most expensive chronic conditions, with heart disease and stroke costing the U.S. healthcare system roughly $214 billion annually. Yet, provider shortages and siloed care teams leave patients with limited care options, gaps in care, and insufficient education and empowerment to self-manage their heart health. Additionally, high treatment costs and resource constraints often limit care to those with the highest acuity conditions. Built using a Cognitive Behavioral Therapy framework and designed in accordance with guidelines from the American Heart Association (AHA), Lark Heart Health will provide a cost-effective, scalable solution for continuous, person-centric remote heart health coaching intended to help users improve their healthy lifestyle behaviors, reduce stress levels, and ultimately decrease risk factors for heart disease. Through an evidence-based educational curriculum and real-time personalized coaching, Lark will provide users with the tools they need to make meaningful lifestyle changes that can help them better prevent and manage ASCVD and CAD. Earlier this year, Lark announced it had joined the AHA's Network at American Heart Association Center of Health Technology & Innovation, which is focused on building and fostering health technology relationships to develop innovative and scalable solutions. "Lark Heart Health will help those at high risk prevent and actively manage cardiovascular disease through personalized digital coaching. By leveraging our AI technology, we can deliver meaningful and engaging care at an unprecedented scale, and this collaboration with Roche Diagnostics will support the expansion of our proven tech platform into one of the costliest chronic disease markets." Julia Hu, co-founder and CEO of Lark About Lark Health Lark is a healthcare technology company aimed at delivering infinitely scalable, virtual chronic and preventative healthcare through conversational AI. To date, Lark has provided nearly 2 million people with unlimited, 24/7 personalized care delivered through an easy-to-use, text message-like interface that integrates remote patient monitoring tools and is built on a cognitive behavioral therapy framework. Lark's platform seamlessly integrates with health plans' and employers' existing healthcare infrastructure to help them scale their chronic disease prevention and management programs, boost engagement, and improve health outcomes. Lark currently works with many of the largest health plans and across four programs: Prevention, Diabetes Prevention, Diabetes Care, and Hypertension Care. Lark's Diabetes Prevention Program, which is the fastest growing and lowest cost DPP, has received the highest level of clinical recognition—Full Recognition—from the Centers for Disease Control and Prevention. The company has received numerous accolades, including having been named as one of CB Insights Digital Health 150 (2019), a finalist for the UCSF Digital Health Awards one of Fast Company's Most Innovative Companies and one of Fierce Healthcare's Fierce 15.

Read More

HEALTH TECHNOLOGY

Alcon Strengthens Leadership in IOL Innovation with Launch of Clareon Portfolio in the U.S.

Alcon | March 07, 2022

Alcon the global leader in eye care dedicated to helping people see brilliantly, announced the launch of the Clareon®family of intraocular lenses (IOLs) in the U.S. Utilizing Alcon’s most advanced IOL material, Clareon can deliver consistent visual outcomes and exceptional clarity that lasts.°,1-7The Clareon clarity is born out of a glistening-free§IOL material that has among the lowest levels of haze and subsurface nanoglistenings compared to leading competitor IOLs.†,*,1-3 “We are proud to offer our latest IOL technology in the U.S. and other countries across the globe. At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients. Clareon is the result of robust R&D efforts at every level—inventive material science, advanced manufacturing techniques and novel delivery systems—to deliver exceptional, long-lasting clarity.” Ian Bell, President, Global Business & Innovation, Alcon The Clareon portfolio leverages many of the same design characteristics and optics as Alcon’s leading IOLs to help deliver the outcomes surgeons expect.8,9Clareon offers sharp, crisp vision with a proprietary edge designed to help reduce glare and posterior capsular opacification.7The lens’ unique and proven STABLEFORCE®Haptics provide superior axial and rotational stability.*,β,8-14Clareon has been extensively researched, with inclusion in 30 published studies worldwide. Clareon Monofocal and Clareon Toric IOLs have already been implanted in more than one million eyes across more than 70 countries.15 Clareon IOLs are inserted using the next-generation, reusable Clareon Monarch®IVDelivery System, which provides precise and controlled implantation and that was designed specifically for the new Clareon material.15,16Clareon Monofocal is also available in the next-generation automated, single-use delivery system, AutonoMe™. “As one of the investigators for the Clareon pivotal trial, I was immediately impressed with the clarity of the new IOL material, delivery system and the consistent refractive outcomes,” said Dr. Samuel H. Lee, MD, Ophthalmologist, Sacramento, CA.** “Today, the clarity of Clareon persists four years later in my trial patients, with the optic performance that I expect from Alcon IOLs, as well as continued high patient satisfaction.” Clareon Monofocal, Clareon PanOptix®, Clareon PanOptix Toric, Clareon Vivity®and Clareon Vivity Toric IOLs are now available in the U.S. Clareon PanOptix offers patients the possibility of 20/20 vision at distance (far), intermediate (at arm’s length) and near (up close), with continuous vision of 20/25 or better.¥,14,17Clareon Vivity is a non-diffractive extended depth of focus lens with wavefront-shaping X-WAVE™ technology, delivering monofocal-quality distance with excellent intermediate and functional near vision and with a monofocal visual disturbance profile.13,18 Clareon Toric will be available in the U.S. later this year. Alcon will be rolling out the Clareon family of IOLs in international markets throughout 2022 and 2023. There are more than 28 million cataract surgeries performed each year in the world. With the aging population and increased life expectancies, these surgeries are expected to increase 3-4% per year for the next 30 years, leading to an estimated 60 million global cataract surgeries annually by 2045.19 About Cataracts A cataract is a cloudy area in the natural lens of the eye that affects vision. As a cataract develops, the eye's lens gradually becomes hard and cloudy, allowing less light to pass through, which makes it more difficult to see. The vast majority of cataracts result from normal aging, but radiation exposure, taking steroids, diabetes and eye trauma can accelerate their development. Cataracts are the most common age-related eye condition and the leading cause of preventable blindness.20Cataracts are treated by removing the eye's cloudy natural lens and surgically replacing it with an IOL. More than 92% of cataract surgeries are considered successful, and patients typically can return to their normal routines within 24 hours.21 About Clareon IOLs and Delivery Systems The family of Clareon intraocular lenses (IOLs) includes the Clareon Aspheric Hydrophobic Acrylic and Clareon Aspheric Toric IOLs, the Clareon PanOptix Trifocal Hydrophobic IOL, Clareon PanOptix Toric, Clareon Vivity Extended Vision Hydrophobic Posterior Chamber IOL and Clareon Vivity Toric IOLs. Each of these IOLs is indicated for visual correction of aphakia in adult patients following cataract surgery. In addition, the Clareon Toric IOLs are indicated to correct pre-existing corneal astigmatism at the time of cataract surgery. The Clareon PanOptix lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. The Clareon Vivity lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity while maintaining comparable distance visual acuity. All of these IOLs are intended for placement in the capsular bag. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting any IOL in a patient with any of the conditions described in the Directions for Use that accompany each IOL. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon, informing them of possible risks and benefits associated with these IOLs. Reference the Directions for Use labelling for each IOL for a complete listing of indications, warnings and precautions. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 24,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care.

Read More

Spotlight

Hospital coding departments have seen a dramatic increase in professional fee coding following the wave of physician group acquisitions in recent years. These facility coding teams are highly skilled at inpatient and outpatient coding but are often challenged by the highly specialized physician-orientated coding subset. This issue is gaining increasing scrutiny as sub-optimal professional fee coding is a compliance risk and can negatively impact the bottom lines of the hospital, and the physicians’ practices for which they support.

Resources